Neurodevelopmental Disorder with Microcephaly, Impaired Language, and Gait Abnormalities (NEDMILG) — Comprehensive Disease Report

Disease: Neurodevelopmental Disorder with Microcephaly, Impaired Language, and Gait Abnormalities (NEDMILG) Causal gene: NARS1 (asparaginyl-tRNA synthetase 1) MONDO ID: MONDO:0100348 OMIM: #619091 (autosomal recessive, NEDMILG); #619092 (autosomal dominant, de novo, with epilepsy — NEDMILEG) Category: Mendelian (rare aminoacyl-tRNA synthetase [ARS] disorder)

Summary

Neurodevelopmental Disorder with Microcephaly, Impaired Language, and Gait Abnormalities (NEDMILG) is a rare Mendelian neurodevelopmental disorder caused by pathogenic variants in NARS1, the gene encoding cytoplasmic asparaginyl-tRNA synthetase (AsnRS/NARS1). The disorder was defined by Manole et al. (2020), who described 32 individuals from 21 families presenting with a recognizable core of progressive microcephaly, neurodevelopmental delay, poor or absent expressive language, gait abnormalities (ataxia and/or spasticity), seizures, and peripheral neuropathy (PMID: 32738225). NARS1 is a housekeeping enzyme that charges asparagine onto its cognate tRNA-Asn, an essential step in cytoplasmic protein synthesis; disease results from impairment of this activity in the developing and mature nervous system.

Two allelic disease entities exist and are best considered together as "NARS1-related neurologic disorders." The autosomal recessive form (biallelic variants; OMIM #619091) acts through partial loss-of-function, while the autosomal dominant form (recurrent de novo heterozygous variants; OMIM #619092) acts through a toxic gain-of-function / dominant-negative mechanism in which the mutant subunit poisons the obligate AsnRS homodimer. Both converge on reduced functional AsnRS activity, decreased global protein synthesis, and — critically for microcephaly — impaired proliferation of radial glial cells (RGCs) in the developing cortex, a mechanism directly demonstrated in patient iPSC-derived cortical organoids and zebrafish (PMID: 32788587; PMID: 40968538; PMID: 40914244).

The most important differential diagnosis is asparagine synthetase deficiency (ASNS deficiency, OMIM #615574), which phenocopies NEDMILG (congenital microcephaly, severe developmental delay, intractable seizures) but is biochemically distinct: ASNS deficiency lowers CSF/plasma asparagine because it impairs asparagine synthesis, whereas NARS1 disease impairs charging of asparagine onto tRNA and leaves asparagine levels normal (PMID: 27422383; PMID: 25663424). This report synthesizes 7 confirmed findings across the 15 requested sections, drawing on 11 reviewed papers, and flags where evidence is strong versus where knowledge gaps remain.

Key Findings

Finding 1 — Disease identity and dual inheritance (F001)

NEDMILG is caused by variants in NARS1 (asparaginyl-tRNA synthetase 1; OMIM 108410; chromosome 18q21.31; HGNC symbol NARS1, formerly NARS; NCBI Gene 4677). The landmark study by Manole et al. (2020, Am J Hum Genet) described 32 individuals from 21 families with both de novo heterozygous and biallelic NARS1* variants who presented with "microcephaly, neurodevelopmental delay, seizures, peripheral neuropathy, and ataxia" (PMID: 32738225).

"Here, we describe 32 individuals from 21 families, presenting with microcephaly, neurodevelopmental delay, seizures, peripheral neuropathy, and ataxia, with de novo heterozygous and bi-allelic mutations in asparaginyl-tRNA synthetase (NARS1)." — Manole et al. 2020

OMIM assigns two entries: NEDMILG #619091 (autosomal recessive, biallelic variants) and NEDMILEG #619092 (autosomal dominant, de novo variants, with epilepsy). Both are unified under MONDO:0100348 and the working label "NARS1-related neurologic disorders."

Finding 2 — Dual molecular mechanism: recessive loss-of-function vs. dominant gain-of-function (F002)

Manole et al. demonstrated reduced NARS1 mRNA expression, protein levels, and enzyme activity in patient fibroblasts and induced neural progenitor cells (iNPCs), and molecular modeling of the recessive variant c.1633C>T (p.Arg545Cys) showed weaker tRNA positioning/selectivity.

"We demonstrate a reduction in NARS1 mRNA expression as well as in NARS1 enzyme levels and activity in both individual fibroblasts and induced neural progenitor cells (iNPCs)." — Manole et al. 2020

"the mechanism for de novo variants could be toxic gain-of-function and for recessive variants, partial loss-of-function" — Manole et al. 2020

A 2025 functional study (Peeples et al.; PMID: 40968538) further showed that dominant NARS1 variants interact with the wild-type subunit and repress its ability to support cellular growth — a dominant-negative mechanism — with CNS+PNS-associated variants more severe than PNS-only variants.

Finding 3 — Core clinical phenotype (F003)

Manole et al. reported patients aged 2–33 years with global developmental delay from infancy, delayed walking, moderate-to-severe intellectual disability, poor/absent language, and small head circumference (most with frank microcephaly, ranging from −2.0 to −8.7 SD). The combined NEDMILG/NEDMILEG phenotype comprises:

• Progressive microcephaly (HP:0000253 Progressive microcephaly / HP:0000252 Microcephaly)
• Impaired intellectual development (HP:0001249)
• Poor or absent expressive language (HP:0002019 / HP:0001344 Absent speech)
• Gait abnormalities — ataxia (HP:0001251) and/or spasticity (HP:0001257 / HP:0002061)
• Variable axial hypotonia (HP:0001252)
• Early-onset seizures (HP:0001250; majority in the dominant NEDMILEG form)
• Peripheral sensorimotor neuropathy (HP:0009830), demyelinating or axonal
• Facial dysmorphism, cerebral atrophy (HP:0002059), and delayed myelination (HP:0012448) on MRI in a subset

"presenting with microcephaly, neurodevelopmental delay, seizures, peripheral neuropathy, and ataxia" — Manole et al. 2020

The course is often neurodegenerative, involving both the central (CNS) and peripheral (PNS) nervous systems.

Finding 4 — Microcephaly arises from impaired radial glial cell proliferation (F004)

Wang et al. (2020, Nat Commun; PMID: 32788587) identified biallelic missense/frameshift NARS1 variants in 7 patients from 3 families. Patient cells showed reduced NARS1 protein, impaired NARS1 activity, and impaired global protein synthesis. Patient-derived cortical brain organoids were significantly smaller (by div52–90), with reduced ventricular-zone Ki67+/phospho-histone-H3+ proliferating cells and increased CC3+ apoptotic cells; single-cell RNA-seq revealed cell-cycle defects in radial glial cells and altered astrocytic/RGC lineages.

"Cortical brain organoid modeling shows reduced proliferation of radial glial cells (RGCs), leading to smaller organoids characteristic of microcephaly." — Wang et al. 2020

"Patient cells show reduced NARS1 protein, impaired NARS1 activity and impaired global protein synthesis." — Wang et al. 2020

Notably, the enzymatic defect is specific to NARS1: TARS, KARS, and RARS activities were unaffected in NARS1-mutant cells, ruling out a general aminoacylation collapse. Manole et al. also showed that injecting mutant NARS1 mRNA into wild-type zebrafish caused dose-dependent cyclopia and gastrulation defects, consistent with a dominant-negative effect in vivo.

Finding 5 — Dominant variants act by a dominant-negative mechanism graded by clinical severity (F005)

Peeples et al. (2026; PMID: 40968538) used yeast complementation to show that pathogenic NARS1 variants are loss-of-function in isolation. When mutant and wild-type human NARS1 were co-expressed, the variants interacted with the wild-type subunit and the majority repressed the wild-type allele's ability to support cellular growth — the hallmark of a dominant-negative effect.

"These studies revealed that NARS1 variants interact with the wild-type subunit and that the majority of variants repress the ability of the wild-type allele to suppo[rt]..." — Peeples et al.

"patients present with either an isolated PNS neuropathy or with a complex phenotype that includes both PNS and central nervous system (CNS) features" — Peeples et al.

NARS1 is one of seven dimeric ARS enzymes implicated in dominant inherited neuropathy, placing it within a broader class of ARS-related neurological disease.

Finding 6 — Structural basis of the recurrent dominant R534* allele: homodimer poisoning (F006)

Vallée et al. (2025, J Biol Chem; PMID: 40914244) characterized the recurrent de novo monoallelic nonsense variant R534* (premature stop codon, 15-residue C-terminal truncation). This allele escapes nonsense-mediated decay and is stably co-expressed with wild-type protein.

"a de novo monoallelic nonsense mutation (R534∗) in the asparaginyl-tRNA synthetase (AsnRS)-resulting in a premature stop codon and 15-residue C-terminal truncation-has been identified in multiple families and is associated with severe neurodevelopmental symptoms" — Vallée et al. 2025

"patient-derived lymphoblasts express similar amounts of wild-type (WT) and mutant (R534∗) AsnRS and exhibit a severe proliferation defect" — Vallée et al. 2025

AsnRS functions as an obligate homodimer. The deleted C-terminal region (R534–P548) contributes to dimerization, tRNA binding, and catalytic-site stabilization; its loss produces wild-type subunit poisoning and heterodimer predominance, explaining the dominant-negative effect. NARS1 protein = UniProt O43776 (548 aa, ~62.9 kDa), a Class II ARS with UNE-N, anticodon-binding, and catalytic domains; the human UNE-N domain structure is deposited as PDB 5XIX.

Finding 7 — Key differential diagnosis: ASNS deficiency (F007)

Asparagine synthetase deficiency (ASNS; OMIM #615574; ASNS gene on 7q21; autosomal recessive) is the closest phenocopy. It presents with severe congenital microcephaly, severe global developmental delay, intractable seizures/hyperekplexia, and spastic quadriplegia; brain MRI shows cerebral atrophy, delayed myelination, and a simplified gyral pattern.

"Asparagine synthetase deficiency (OMIM# 615574) is a very rare newly described neurometabolic disorder characterized by congenital microcephaly and severe global developmental delay, associated with intractable seizures or hyperekplexia." — Seidahmed et al. 2016 (PMID: 27422383)

"we demonstrated low CSF and plasma asparagine in both patients" — Alfadhel et al. 2015 (PMID: 25663424)

The decisive discriminator is asparagine level: low CSF/plasma asparagine in ASNS deficiency (a synthesis defect) versus normal asparagine in NARS1 disease (a tRNA-charging defect). Both overlap clinically, so molecular testing plus asparagine measurement is required to distinguish them. (Note: asparagine supplementation in ASNS deficiency has been reported to worsen seizures — PMID: 27268761.)

Comprehensive Section-by-Section Report

1. Disease Information

Overview. NEDMILG is a rare Mendelian neurodevelopmental disorder within the family of aminoacyl-tRNA synthetase (ARS) diseases. It is defined by progressive microcephaly, impaired/absent expressive language, gait abnormalities, intellectual disability, and variable seizures and peripheral neuropathy, caused by dysfunction of cytoplasmic asparaginyl-tRNA synthetase (NARS1) (PMID: 32738225).

Key identifiers. | Resource | Identifier | |---|---| | MONDO | MONDO:0100348 | | OMIM (recessive) | #619091 (NEDMILG) | | OMIM (dominant, +epilepsy) | #619092 (NEDMILEG) | | Gene OMIM | *108410 (NARS1) | | HGNC | NARS1 (formerly NARS) | | NCBI Gene | 4677 | | UniProt | O43776 | | Cytoband | 18q21.31 |

Synonyms / alternative names. NARS1-related neurodevelopmental disorder; asparaginyl-tRNA synthetase deficiency; NEDMILG (recessive) and NEDMILEG (dominant, with epilepsy); "NARS1-related neurologic disorders" (umbrella term).

Information source. Derived from aggregated disease-level resources and primary case series (cohorts of 32 and 7 patients), not from EHR/individual-patient population registries.

2. Etiology

Causal factors. Purely genetic — pathogenic variants in NARS1. No environmental or infectious cause is implicated.

Genetic risk factors. Biallelic NARS1 variants (recessive NEDMILG) or a single de novo heterozygous variant (dominant NEDMILEG). Recurrent alleles include the dominant nonsense R534* and recessive missense variants such as p.Arg545Cys (c.1633C>T) (PMID: 32738225; PMID: 40914244). Consanguinity increases risk of the recessive form. No validated modifier genes or protective alleles are established. No environmental risk or protective factors, and no gene-environment interactions, are described for this monogenic disorder.

3. Phenotypes

Severity/progression. Severity is variable but often moderate-to-severe; the course is frequently progressive/neurodegenerative, affecting both CNS and PNS (PMID: 32738225). Quality of life is substantially impacted by intellectual disability, absent language, and impaired mobility; formal QoL instrument data are not available for this ultra-rare disorder.

4. Genetic / Molecular Information

Causal gene. NARS1 (OMIM *108410), encoding cytoplasmic asparaginyl-tRNA synthetase (UniProt O43776, 548 aa, ~62.9 kDa; Class II ARS with UNE-N, anticodon-binding, and catalytic domains).

Variant types. Missense (e.g., p.Arg545Cys), frameshift, and nonsense (e.g., R534*). Recessive disease requires biallelic hypomorphic alleles; dominant disease results from single de novo variants.

Functional consequences. - Recessive: partial loss-of-function — reduced mRNA, protein, and enzyme activity (PMID: 32738225). - Dominant: dominant-negative / toxic gain-of-function — mutant subunit poisons the homodimer (PMID: 40968538; PMID: 40914244).

The R534* transcript escapes NMD and is expressed at levels comparable to wild-type. No epigenetic mechanisms or large chromosomal abnormalities are implicated; disease is at the single-gene level. No established modifier genes.

5. Environmental Information

Not applicable. NEDMILG is a monogenic disorder with no known environmental, lifestyle, or infectious contributors.

6. Mechanism / Pathophysiology

Core pathway. NARS1 catalyzes aminoacylation of tRNA-Asn (charging asparagine onto tRNA), an essential step in cytoplasmic mRNA translation (GO:0006421 asparaginyl-tRNA aminoacylation; GO:0006412 translation). Loss of this activity reduces global protein synthesis (PMID: 32788587).

Causal chain for microcephaly:

NARS1 variant
   │ (recessive: partial LoF ; dominant: homodimer poisoning)
   ▼
Reduced functional AsnRS activity
   ▼
Impaired tRNA-Asn charging → decreased global protein synthesis
   ▼
Radial glial cell (RGC) cell-cycle defect / reduced proliferation
   +  increased apoptosis (↑ CC3+)
   ▼
Smaller ventricular zone / fewer neurons → smaller cortex
   ▼
Progressive MICROCEPHALY + intellectual disability + language/gait deficits

Cellular processes. Cell-cycle dysregulation and apoptosis in radial glial cells (CL:0000681 radial glial cell) of the ventricular zone; altered astrocytic/RGC lineage specification (scRNA-seq) (PMID: 32788587). Peripheral neuropathy reflects the high translational demand of neurons/Schwann-cell–supported axons, a recurring theme across dimeric ARS neuropathies (PMID: 40968538).

Protein dysfunction. AsnRS is an obligate homodimer; the C-terminal R534–P548 region supports dimerization, tRNA binding, and catalytic-site stabilization. Truncation (R534*) yields heterodimer predominance and dominant-negative poisoning (PMID: 40914244).

Suggested GO/CL terms: GO:0004816 (asparagine-tRNA ligase activity), GO:0006421 (asparaginyl-tRNA aminoacylation), GO:0006412 (translation), GO:0008285 (negative regulation of cell proliferation), GO:0006915 (apoptotic process); CL:0000681 (radial glial cell), CL:0000127 (astrocyte), CL:0000540 (neuron). Subcellular: GO:0005737 (cytoplasm).

7. Anatomical Structures Affected

• Primary organ/system: Brain / central nervous system (UBERON:0000955 brain; UBERON:0001950 neocortex; UBERON:0002435 ventricular zone), plus peripheral nervous system (UBERON:0000010).
• Cell level: Radial glial cells (CL:0000681), neurons (CL:0000540), astrocytes (CL:0000127); peripheral nerve axons/Schwann cells.
• Subcellular: Cytoplasm (GO:0005737), where cytoplasmic translation occurs.
• Lateralization: Bilateral, symmetric (microcephaly and diffuse cortical involvement).

8. Temporal Development

• Onset: Congenital to early infancy (microcephaly may be progressive postnatally); developmental delay evident from infancy.
• Progression: Often chronic and progressive/neurodegenerative, involving both CNS and PNS; seizures frequently early-onset (dominant form).
• Duration: Lifelong.
• Critical period: Prenatal/early postnatal corticogenesis is the window in which reduced RGC proliferation produces microcephaly — the key period for any hypothetical intervention.

9. Inheritance and Population

• Inheritance: Autosomal recessive (NEDMILG #619091, biallelic) and autosomal dominant de novo (NEDMILEG #619092).
• Epidemiology: Ultra-rare; precise prevalence/incidence not established. Fewer than ~40 families reported to date (32 individuals/21 families in Manole 2020; 7/3 in Wang 2020; additional R534* families).
• Penetrance/expressivity: Appears high penetrance with variable expressivity (severity ranges from isolated peripheral neuropathy to combined CNS+PNS disease for dominant alleles).
• Consanguinity: Increases recessive-form risk. Founder effects, anticipation, and germline mosaicism are not established. Carrier frequency is presumed very low but not quantified.
• Sex ratio: No strong sex bias reported (autosomal gene).

10. Diagnostics

• Genetic testing (definitive): Whole-exome or whole-genome sequencing, or a neurodevelopmental/microcephaly/neuropathy gene panel including NARS1; variant classification per ACMG/AMP with ClinVar/ClinGen review. Single-gene NARS1 testing appropriate when phenotype is highly suggestive.
• Imaging: Brain MRI may show microcephaly, cerebral atrophy, and delayed myelination.
• Electrophysiology: Nerve conduction studies/EMG to characterize demyelinating vs. axonal neuropathy; EEG for seizures.
• Biochemistry (differential): Plasma/CSF asparagine — normal in NARS1 disease but low in ASNS deficiency — is the pivotal discriminator (PMID: 25663424).
• Differential diagnosis: ASNS deficiency (#615574; low asparagine, simplified gyral pattern), other ARS-related NDDs, and syndromic microcephalies. Overlapping-phenotype genes noted during investigation include ACBD6 (PMID: 37951597), PAK3 (PMID: 41223971), and Angelman-spectrum conditions (PMID: 34042275) — distinguishable by molecular testing.

11. Outcome / Prognosis

• Survival/mortality: Not systematically quantified; the disorder is chronic and can be neurodegenerative. Severe forms carry substantial morbidity.
• Morbidity/function: Major long-term disability from intellectual disability, absent language, impaired gait/mobility, seizures, and neuropathy.
• Prognostic factors: Genotype tracks severity — CNS+PNS-associated dominant variants are more severe than PNS-only variants (PMID: 40968538); recessive hypomorphic combinations and degree of microcephaly likely correlate with cognitive outcome.
• Recovery potential: No disease-modifying therapy; deficits are generally permanent.

12. Treatment

No disease-specific or curative therapy exists. Management is supportive and multidisciplinary: - Antiseizure medications for epilepsy (NCIT anticonvulsant agents). - Physical, occupational, and speech/language therapy for gait, motor function, and communication. - Developmental/educational support for intellectual disability. - Orthopedic/neurology management of spasticity and peripheral neuropathy. - Nutritional support as needed.

Caution: asparagine supplementation is not a rational therapy for NARS1 disease (asparagine levels are normal); in the phenocopy ASNS deficiency, supplementation worsened seizures (PMID: 27268761). No approved gene, cell, or RNA therapies; none in registered trials specific to NARS1 at the time of review.

13. Prevention

• Genetic counseling for families: recurrence risk 25% for recessive (both parents carriers) and typically low (de novo) but with germline-mosaicism caveat for dominant cases.
• Prenatal testing / preimplantation genetic testing available once the familial variant(s) are known.
• Carrier/cascade screening in consanguineous families.
• No primary prevention (no environmental cause), immunization, or public-health intervention applies.

14. Other Species / Natural Disease

• NARS1 orthologs are conserved (mouse Nars, zebrafish nars). No naturally occurring animal disease is catalogued in OMIA for NARS1. Zebrafish injected with mutant NARS1 mRNA developed cyclopia and gastrulation defects, demonstrating cross-species conservation of the dominant-negative effect (PMID: 32738225). No zoonotic or cross-species transmission (genetic disorder).

15. Model Organisms

Phenotype recapitulation: Cortical organoids strongly recapitulate the microcephaly mechanism (RGC proliferation). Zebrafish captures the dominant-negative developmental toxicity. Limitations: no reported knock-in mouse recapitulating the full CNS+PNS phenotype; organoids do not model peripheral neuropathy, seizures, or long-term neurodegeneration.

Mechanistic Model / Interpretation

The genetics, biochemistry, and developmental biology converge on a single unifying model. Two genetically distinct routes — recessive partial loss-of-function and dominant homodimer poisoning — both reduce the pool of catalytically competent AsnRS. Because asparaginyl-tRNA charging is rate-limiting for translation, the downstream consequence is reduced global protein synthesis, which is especially damaging to highly proliferative radial glial cells during corticogenesis and to metabolically demanding neurons/axons in the periphery.

RECESSIVE alleles                 DOMINANT alleles (e.g., R534*)
(biallelic hypomorph)             (de novo heterozygous)
│                                   │
↓ mRNA/protein/activity            mutant subunit escapes NMD,
(partial loss-of-function)         co-expressed with WT
│                                   │
│                          poisons obligate homodimer
└───────────────┬───────────────────┘  (heterodimer predominance)
                ▼
 REDUCED FUNCTIONAL AsnRS ACTIVITY
                ▼
 ↓ tRNA-Asn charging → ↓ global protein synthesis
        ┌───────────────┴───────────────┐
        ▼                                 ▼
↓ RGC proliferation + ↑ apoptosis        neuron/axon vulnerability
        ▼                                 ▼
      MICROCEPHALY, ID,                   PERIPHERAL NEUROPATHY
     language & gait deficits              (± ataxia, spasticity)

The genotype–severity gradient for dominant alleles (isolated PNS neuropathy → combined CNS+PNS disease) is best explained by the degree of dominant-negative poisoning: more disruptive alleles (like the truncating R534*) more severely compromise the shared enzyme pool, extending damage from the periphery into the developing cortex. This places NARS1 disease firmly within the broader class of dimeric ARS neuropathies/neurodevelopmental disorders, where dosage of functional enzyme is the shared limiting variable.

Evidence Base

All confirmed findings are anchored in the verified abstract quotes reproduced above.

Limitations and Knowledge Gaps

1. Ultra-rare with small cohorts. Fewer than ~40 families are reported; prevalence, incidence, penetrance, carrier frequency, survival, and formal QoL metrics are unquantified.
2. No mammalian in vivo model fully recapitulating the combined CNS+PNS phenotype is reported; existing models (organoids, zebrafish, yeast, lymphoblasts) each capture only part of the disease.
3. Peripheral neuropathy mechanism is inferred by analogy to other ARS neuropathies rather than directly dissected for NARS1.
4. Genotype–phenotype correlations are still emerging; the recessive-allele severity map is less complete than for dominant alleles.
5. No therapeutics. No disease-modifying treatment or registered NARS1-specific trial exists.
6. Epigenetic, immune, and metabolomic dimensions were not part of the primary literature and appear not applicable, but have not been formally excluded.

Proposed Follow-up Experiments / Actions

1. Generate a knock-in mouse (e.g., R534* and a representative recessive allele) to model CNS+PNS disease, seizures, and progression not captured by organoids.
2. Systematic genotype–phenotype mapping across all reported alleles using standardized yeast/organoid assays to build a predictive severity scale (extending Peeples/Vallée).
3. Peripheral-nerve-specific models (iPSC-derived motor neurons, Schwann-cell co-cultures) to directly test the translation-demand hypothesis for neuropathy.
4. Ribosome profiling / proteomics in patient RGCs to identify which specific transcripts/proteins are most sensitive to reduced tRNA-Asn charging (candidate downstream effectors).
5. Natural-history registry to quantify prevalence, progression rate, seizure burden, and prognostic biomarkers.
6. Preclinical therapeutic screens — e.g., allele-selective knockdown of the toxic dominant allele (ASO/siRNA) to relieve homodimer poisoning; small molecules that stabilize the AsnRS dimer.
7. Confirm asparagine normalcy in a NARS1 cohort to formally validate the CSF/plasma asparagine test as the routine discriminator from ASNS deficiency.

Report compiled from a 5-iteration autonomous investigation: 7 confirmed findings, 11 papers reviewed. All quoted abstract excerpts were verified against stored abstracts during the investigation.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.